JacquesGalipeauMD
Hematology • Madison, WIAssociate Dean for Therapeutics Development, University of Wisconsin - Madison School of Medicine and Public Health. Hematologist, Department of Medicine
Dr. Galipeau is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
600 Highland Ave
Madison, WI 53792Phone+1 608-265-1700Fax+1 608-266-6020
Summary
- Jacques Galipeau, M.D. FRCP(C) obtained his Medical Degree from the University of Montreal and completed specialty training in internal medicine at McGill University. He went on to the Tufts-affiliated New England Medical Center in Boston for three years of subspecialty training in Hematology & Medical Oncology followed by a two-year scientific fellowship in gene Therapy at St-Jude Children’s research hospital in Memphis Tennessee.
Starting in 1997, Dr. Galipeau served as faculty at McGill University before joining Emory University in 2009 as a Professor of Hematology & Oncology and Director of the Emory Personalized Immunotherapy Center. Since September 2016, he has been the Don and Marilyn Anderson Professor of Oncology within the Department of Medicine and UW Carbone Comprehensive Cancer Center at the University of Wisconsin in Madison, and is the inaugural Associate Dean for Therapeutics Discovery and Development at the University of Wisconsin School of Medicine & Public Health
Dr. Galipeau has initiated and developed an NIH-funded research program in the study and use of mesenchymal stromal cells as an immunotherapy of catastrophic illnesses including cancer and immune disease. He is an internationally recognized expert in translational development of cell therapies and the sponsor of a series of FDA-sanctioned clinical trials examining the use of autologous marrow-derived mesenchymal stromal cells for immune disorders, including Crohn’s disease and graft vs host disease.
He is also the director of the University of Wisconsin Advanced Cell Therapy Program whose mission is to develop personalized cell therapies for immune and malignant disorders and to promote and deploy first-in-human clinical trials of UW cell therapy innovations to improve outcomes for children and adults.
Dr. Galipeau is a board certified Hematologist with an active clinical practice in consultative benign hematology.
Clinical Expertise
- Hematology, Regenerative medicine, General / Benign hematology, experimental cell therapy, virus specific T-cells, mesenchymal stromal cells, first-in-human clinical trials
Education & Training
Tufts Medical CenterFellowship, Hematology and Medical Oncology, 1992 - 1995
University of Montreal Faculty of MedicineClass of 1988
Certifications & Licensure
WI State Medical License 2016 - 2025
GA State Medical License 2009 - 2017- American Board of Internal Medicine Hematology
Awards, Honors, & Recognition
- GRA Distinguished Cancer Scientist 2009
- Fonds de la recherche en sante du Quebec chercheur-boursier senior 2006
- Excellence in Research Sir Mortimer B. Davis Jewish General Hospital, 2004
- Join now to see all
Clinical Trials
- Treatment of Cytomegalovirus (CMV) Infections With Viral-Specific T Cells Start of enrollment: 2020 Feb 06
- A Dose-Escalation Study Evaluating Safety and Tolerability of Viral-Specific T Cells Against CMV in Adult Solid Organ Transplant Recipients Start of enrollment: 2019 Sep 27
Publications & Presentations
PubMed
- 18 citationsAdoptive transfer of mesenchymal stromal cells accelerates intestinal epithelium recovery of irradiated mice in an interleukin-6-dependent manner.Moïra François, Elena Birman, Kathy-Ann Forner, Louis Gaboury, Jacques Galipeau
Cytotherapy. 2012-10-15 - 98 citationsRoles of FGF signaling in stem cell self-renewal, senescence and aging.Daniel L. Coutu, Jacques Galipeau
Aging. 2011-10-09 - 98 citationsEndothelial NO-Synthase Gene-Enhanced Progenitor Cell Therapy for Pulmonary Arterial Hypertension: the PHACeT TrialJohn Granton, David Langleben, Michael B. Kutryk, Nancy J. Camack, Jacques Galipeau
Circulation Research. 2015-07-20
Journal Articles
- GM-CSF and IL-4 fusion cytokine Induces B Cell-dependent Hematopoietic RegenerationJiusheng Deng, Andrea Pennati, Shala Yuan, Jian Hui Wu, Krishnendu Roy, Edmund Waller, Jacques Galipeau, Mol Ther, 1/1/2017
- Bone Marrow Derived Mesenchymal Stromal Cells From Sickle Cell Disease Patients Display Intact FunctionalityElizabeth O. Stenger, Raghavan Chinnadurai, Shala Yuan, Marco Garcia, Dalia Arafat, Greg Gibson, Lakshmanan Krishnamurti, and Jacques Galipeau, Biol Blood Marrow Transplant, 1/1/2017
- GIFT4 Fusokine Converts Leukemic B Cells into Anti-CLL EffectorsJiusheng Deng, Andrea Pennati, Yuanqiang Wu, Jonathon B. Cohen, Spencer Ng, Jian Hui Wu, Christopher R. Flowers, and Jacques Galipeau, J Transl Med, 1/1/2016
- Join now to see all
Books/Book Chapters
Lectures
- The MSC conundrum of unmet translational expectations-analysis and potential fixes.Boston, MA - 1/29/2016
- MSCs: Ability, Potency and Comparability.St. Jude Children’s Research Hospital, Memphis, TN - 1/29/2016
- MSC product for clinical trials: manufacturing and potency considerations.Boston, MA - 1/27/2016
- Join now to see all
Press Mentions
The Future of Cell Therapy: Novel Study Tests Treatment for Radiation-Induced Dry MouthMay 31st, 2022- UW Carbone Cancer Center Receives FDA Clearance to Test New Regenerative Medicine Therapy for Radiotherapy-Induced Dry MouthSeptember 8th, 2020
- ONLINE: Taking down Cancer with TechAugust 18th, 2020
- Join now to see all
Other Languages
- French
External Links
- Program for Advanced Cell Therapyhttp://www.pact.wisc.edu
- Linkedinhttps://www.linkedin.com/in/jacquesgalipeau/
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
